Holen Sie sich die Stockscreener-App
4.64
11.00%
0.46
Handel nachbörslich:
4.55
-0.09
-1.94%
Schlusskurs vom Vortag:
$4.18
Offen:
$4.22
24-Stunden-Volumen:
2.15M
Relative Volume:
1.40
Marktkapitalisierung:
$392.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-95.90M
KGV:
-3.5152
EPS:
-1.32
Netto-Cashflow:
$-79.09M
1W Leistung:
+0.00%
1M Leistung:
-16.09%
6M Leistung:
-39.50%
1J Leistung:
-16.70%
1-Tages-Spanne:
$4.22
$4.72
1-Wochen-Bereich:
$4.165
$4.7324
52-Wochen-Spanne:
$4.165
$11.40
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Firmenname
Terns Pharmaceuticals Inc
Sektor
Branche
Telefon
650-525-5535 EXT.101
Adresse
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Vergleichen Sie TERN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
4.64 | 392.84M | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-06-22 | Eingeleitet | Mizuho | Buy |
| 2023-06-07 | Eingeleitet | Jefferies | Buy |
| 2023-05-31 | Eingeleitet | ROTH MKM | Buy |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-02-07 | Eingeleitet | UBS | Buy |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-09-14 | Fortgesetzt | Goldman | Buy |
| 2021-03-02 | Eingeleitet | Cowen | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Buy |
| 2021-03-02 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Terns Pharmaceuticals Inc Aktie (TERN) Neueste Nachrichten
Terns Pharmaceuticals stock hits 52-week low at $4.32 - MSN
Oppenheimer maintains Terns stock Outperform rating, $20 target - MSN
As wheel Terns in CML, Novartis’ Scemblix in crosshairs - BioWorld Online
Objective long/short (TERN) Report - Stock Traders Daily
Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Terns Pharmaceuticals to Present at J.P. Morgan Healthcare ConferenceKey Updates Expected - StockTitan
Terns Pharmaceuticals' chief medical officer sells $25,607 in stock By Investing.com - Investing.com Nigeria
Jill M. Quigley Sells 6,240 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock - MarketBeat
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Insider Emil Kuriakose Sells 4,481 Shares - MarketBeat
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Director Jill M. Quigley Sells 8,760 Shares - MarketBeat
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Mark J. Vignola Sells 8,129 Shares - MarketBeat
Mark J. Vignola Sells 9,059 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock - MarketBeat
Terns Pharmaceuticals CFO Mark J. Vignola sells $99,022 in stock By Investing.com - Investing.com Nigeria
Terns Pharmaceuticals CFO Mark J. Vignola sells $99,022 in stock - Investing.com
Terns Pharmaceuticals' chief medical officer sells $25,607 in stock - Investing.com
Exciting Hire at Terns Pharma! New Employee Receives Special Stock Grant! - Jomfruland.net
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Terns Pharmaceuticals Awards New Employee Stock Options at $5.54 Per Share - StockTitan
Geode Capital Management LLC Grows Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Sold by State Street Corp - Defense World
Terns Pharmaceuticals (NASDAQ:TERN) Trading Down 4.7%Should You Sell? - MarketBeat
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Terns Pharmaceuticals' SWOT analysis: promising pipeline drives stock potential - Investing.com
Is Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Insider Monkey
The Manufacturers Life Insurance Company Has $551,000 Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stake Reduced by Fmr LLC - MarketBeat
Insider Spends US$110k Buying More Shares In Terns Pharmaceuticals - Simply Wall St
Terns Pharmaceuticals CEO & Director Acquires 423% More Stock - Yahoo Finance
Terns Pharmaceuticals (NASDAQ:TERN) Shares Gap Up Following Insider Buying Activity - Defense World
Terns pharmaceuticals CEO Amy Burroughs acquires $110,467 in stock - Investing.com India
Terns pharmaceuticals CEO Amy Burroughs acquires $110,467 in stock By Investing.com - Investing.com Canada
17,369 Shares in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Bought by Intech Investment Management LLC - Defense World
Terns Pharmaceuticals' SWOT analysis: stock poised for growth amid clinical milestones By Investing.com - Investing.com South Africa
Terns Pharmaceuticals' SWOT analysis: stock poised for growth amid clinical milestones - Investing.com
Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial - MSN
Walleye Capital LLC Takes $1.55 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - MarketBeat
Terns’s stock soars as analysts cheer leukemia data — and predict more gains - MSN
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Acquired by Parkman Healthcare Partners LLC - MarketBeat
Cinctive Capital Management LP Buys Shares of 168,564 Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - MarketBeat
Terns reports positive early results in CML drug trial By Investing.com - Investing.com Nigeria
U.S. STOCKS BlackRock, Terns Pharma, PSQ Holdings - XM
Terns Pharmaceuticals Reports Inducement Grant to New Employee under Nasdaq Listing Rule 5635(4) - Marketscreener.com
Finanzdaten der Terns Pharmaceuticals Inc-Aktie (TERN)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):